It’s rarely a wise idea to own a company simply because you think it’s an acquisition target, but if there was ever a generic drug maker worth making that bet on, it’s Taro Pharmaceuticals (TARO).
Sun Pharma has already made an offer that was ultimately rejected by shareholders, which was probably the right move. Even with the stock’s 137% runup since the end of last year, shares are still priced at only 11.6 times their trailing earnings. That’s a buyout target at a bargain price.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities.